Do high plasma free fatty acids lower central serotonergic responsivity?
ID
Source
Brief title
Condition
- Hypothalamus and pituitary gland disorders
- Lipid metabolism disorders
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Prolactin response as a reflection of serotonergic response in the
hypothalamus.
Secondary outcome
na
Background summary
SSRI's causes pituitary prolactin secretion. Atherosclerosis and metabolic
syndrome causes blunted prolactin response. Both diseases are associated with
elevated free fatty acids. Patient with familial combined hyperlipidemia (FCH)
also have high free fatty acids. Studies in rodents suggest an important role
in the regulation of triglyceride synthesis, an important aspect of the
dyslipidemic components of FCH. In this study we will get more insight in the
effect of serotonergic functionality with and without high free fatty acids
with a citalopram provocation test.
Study objective
Do high plasma free fatty acids lower central serotonergic responsivity?
Study design
Serotonergic responsivity is measured after administration of a selective
serotonin reuptake inhibitor, citalopram. This will be done in 10 healthy
subjects will visit the AMC 3 times.
Visit 1 Screening, with general physical check up, and 1 blood withdrawal
Visit 2 Standardized infusion of SSRI with or without increase of free fatty
acids or water.
Visit 3 Standardized infusion of SSRI with or without increase of free fatty
acids or water, opposite to visit 2.
Intervention
Infusion with free fatty acids, heparin and citalopram
Study burden and risks
Healthy volunteers will visit our clinic three times. A total of 490 ml venous
blood will be drawn. A selective serotonine reuptake inhibitor is giving as a
standardized serotonergic test. The side effects of selective serotonin
reuptake inhibitor, heparin and Intralipid are described in the protocol.
Meibergdreef 9
1105 AZ Amsterdam
NL
Meibergdreef 9
1105 AZ Amsterdam
NL
Listed location countries
Age
Inclusion criteria
Male, 18-60 years old, BMI 20-25, stable for 3 months prior the study.
Exclusion criteria
BMI between19-25, Lipid disorder, alchohol abuse, smoking, active disease influencing the protocol, irregular eating patterns, diabetes, brain disease, intense training, medication influencing the nervous system. DM or DM in first degree family member.
Design
Recruitment
Medical products/devices used
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| EudraCT | EUCTR2009-010061-23-NL |
| CCMO | NL25223.018.09 |